DDrare: Database of Drug Development for Rare Diseases

Allo-hmscs (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
211	Hypoplastic left heart syndrome	1
299	Cystic fibrosis	1

211. Hypoplastic left heart syndrome [ 20 clinical trials, 28 drugs, (DrugBank: 9 drugs), 5 drug target genes, 13 drug target pathways]

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 20 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02398604 (ClinicalTrials.gov)	April 2015	24/12/2014	Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome	Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.	Hypoplastic Left Heart Syndrome	Drug: Allo-hMSCs;Drug: Placebo	Joshua M Hare	University of Maryland, College Park	Terminated	N/A	30 Days	All	5	Phase 1	United States

299. Cystic fibrosis [ 1,592 clinical trials, 1,539 drugs, (DrugBank: 255 drugs), 81 drug target genes, 162 drug target pathways]

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 1,592 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03058068 (ClinicalTrials.gov)	December 2020	6/2/2017	Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis	A Phase I, Randomized and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis - HAPI	Cystic Fibrosis	Biological: Allo-hMSCs;Biological: Placebo	Joshua M Hare	NULL	Withdrawn	20 Years	45 Years	All	0	Phase 1	United States